Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the first quarter of 2024.
- Net revenue was $982 million in the first quarter, which is down 4% as reported, and 6% in constant currency from Q1 2023
- Overall organic net revenue decreased by 8% year-over-year during the three-month period
- The company reported a net loss of $715 million for the September quarter, including non-cash goodwill impairment charges of $700 million
- On a per-share basis, Q1 loss was $3.94, vs. breakeven in the year-ago quarter
- Q1 adjusted net loss was $19 million or $0.10 per share, compared to adjusted profit of $61 million or $0.34 per share last year
- Adjusted EBITDA came in at $115 million, down 38% as reported, and 39% in constant currency, compared to last year
- For fiscal 2024, the company expects net revenue to be in the range of $4.30 billion to $4.50 billion
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Trxade Health Inc. (NASDAQ: MEDS) Q1 2024 Research Summary
Trxade Health, Inc. (NASDAQ: MEDS) is a drug procurement and delivery platform that digitalizes the retail pharmacy experience. The company has a growing network of suppliers and partnerships with independent
Earnings Preview: Walmart (WMT) expected to report sales and profit gains in Q1
Over the years, Walmart Inc. (NYSE: WMT) has constantly diversified while maintaining its dominance in the retail world. The company is preparing to report financial results for the first three
After a positive year, what’s in the cards for Electronic Arts (EA) in FY25
Electronic Arts (NASDAQ: EA) ended fiscal 2024 on a mixed note, reporting lower revenues and improved bottom-line performance for the fourth quarter. The stock declined following the announcement as earnings
